{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5eaeb1c98ad11b317bf47794/5eaee09987abd3580dc638af?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"GHB with Shalini Arunogiri","description":"<p>Suzi Gage interviews Shalini Arunogiri about her research on GHB-related harms</p><p><br></p><p>The research can be found here:&nbsp;<a href=\"https://gate.sc/?url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fadd.14848&amp;token=21e72b-1-1588518988424\" rel=\"noopener noreferrer\" target=\"_blank\">onlinelibrary.wiley.com/doi/10.1111/add.14848</a></p><p><br></p><p>Arunogiri, S.,&nbsp;Moayeri, F.,&nbsp;Crossin, R.,&nbsp;Killian, J. J.,&nbsp;Smith, K.,&nbsp;Scott, D., and&nbsp;Lubman, D. I.&nbsp;(&nbsp;2020)&nbsp;Trends in gamma‐hydroxybutyrate‐related harms based on ambulance attendances from 2012 to 2018 in Victoria, Australia.&nbsp;<em>Addiction</em>,&nbsp;115:&nbsp;473–&nbsp;479.&nbsp;<a href=\"https://doi.org/10.1111/add.14848\" rel=\"noopener noreferrer\" target=\"_blank\">https://doi.org/10.1111/add.14848</a>.</p>","author_name":"Addiction journal"}